Annual Financials for Moderna Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
205.83M | 135.07M | 60.21M | 803.4M | 18.41B | |
Sales Growth |
- | -34.38% | -55.42% | 1,234.34% | 2,191.90% | |
Cost of Goods Sold (COGS) incl. D&A |
20.54M | 24.86M | 31.02M | 39.18M | 2.85B | |
COGS excluding D&A |
- | - | - | 7.93M | 2.62B | |
Depreciation & Amortization Expense |
20.54M | 24.86M | 31.02M | 31.25M | 232M | |
Depreciation |
20.54M | 24.86M | 31.02M | 31.25M | 232M | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | 21.06% | 24.77% | 26.31% | 7,170.82% | |
Gross Income |
185.29M | 110.21M | 29.19M | 764.21M | 15.56B | |
Gross Income Growth |
- | -40.52% | -73.52% | 2,518.24% | 1,936.61% | |
Gross Profit Margin |
- | - | - | - | 84.53% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
454.64M | 579.07M | 574.91M | 1.53B | 2.33B | |
Research & Development |
410.46M | 509.68M | 465.29M | 1.34B | 1.76B | |
Other SG&A |
44.19M | 69.39M | 109.62M | 188.27M | - | |
SGA Growth |
- | 27.37% | -0.72% | 165.67% | 52.29% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | - | 1.6M | - | |
EBIT after Unusual Expense |
- | - | - | (764.74M) | - | |
Non Operating Income/Expense |
(1.74M) | 4.93M | (914,000) | 5.4M | 47M | |
Non-Operating Interest Income |
15.24M | 27.02M | 38.53M | 24.72M | 18M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
132,000 | 3.1M | 6.61M | 9.89M | 18M | |
Interest Expense Growth |
- | 2,245.45% | 113.57% | 49.52% | 82.08% | |
Gross Interest Expense |
132,000 | 3.1M | 6.61M | 9.89M | 18M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(256M) | (440.01M) | (514.72M) | (744.51M) | 13.29B | |
Pretax Income Growth |
- | -71.88% | -16.98% | -44.65% | 1,884.39% | |
Pretax Margin |
- | - | - | - | 72.15% | NA |
Income Tax |
(80,000) | (55.27M) | (695,000) | 2.55M | 1.08B | |
Income Tax - Current Domestic |
(80,000) | 326,000 | 505,000 | 32,000 | 1.34B | |
Income Tax - Current Foreign |
- | - | - | 2.52M | 40M | |
Income Tax - Deferred Domestic |
- | - | (1.2M) | - | (294M) | |
Income Tax - Deferred Foreign |
- | - | - | - | (2M) | |
Income Tax Credits |
- | 55.6M | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | (4.13M) | - | - | - | |
Consolidated Net Income |
(255.92M) | (388.86M) | (514.02M) | (747.06M) | 12.2B | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(255.92M) | (388.86M) | (514.02M) | (747.06M) | 12.2B | |
Net Income Growth |
- | -51.95% | -32.19% | -45.34% | 1,733.33% | |
Net Margin Growth |
- | - | - | - | 66.27% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(255.92M) | (388.86M) | (514.02M) | (747.06M) | 12.2B | |
Preferred Dividends |
13.93M | 13M | - | - | - | |
Net Income Available to Common |
(269.84M) | (401.86M) | (514.02M) | (747.06M) | 12.2B | |
EPS (Basic) |
(1.92) | (4.95) | (1.55) | (1.96) | 30.28 | |
EPS (Basic) Growth |
- | -158.38% | 68.63% | -26.08% | 1,645.50% | |
Basic Shares Outstanding |
140.6M | 81.11M | 330.8M | 381.33M | 403M | |
EPS (Diluted) |
(1.92) | (4.95) | (1.55) | (1.96) | 28.31 | |
EPS (Diluted) Growth |
- | -158.38% | 68.63% | -26.08% | 1,545.10% | |
Diluted Shares Outstanding |
140.6M | 81.11M | 330.8M | 381.33M | 431M | |
EBITDA |
(248.82M) | (444M) | (514.7M) | (731.89M) | 13.47B | |
EBITDA Growth |
- | -78.44% | -15.92% | -42.20% | 1,940.43% | |
EBITDA Margin |
- | - | - | - | 73.15% | NA |